

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for December 2024

## Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Alprazolam	Xanax	ALPRAZOLAM	1 mg	tablet	02397056
Jamp Pharma Corporation	Jamp Alprazolam	Xanax	ALPRAZOLAM	2 mg	tablet	02397064
Auro Pharma Inc.	Auro-Bilastine	Blexten	BILASTINE	20 mg	tablet	02541556
Mantra Pharma Inc.	M-Metformin	Glucophage	METFORMIN HCL	850 mg	tablet	02547775
Auro Pharma Inc	Auro-Mirtazapine	Remeron	MIRTAZAPINE	15 mg	tablet	02411695
Auro Pharma Inc	Auro-Mirtazapine	Remeron	MIRTAZAPINE	45 mg	tablet	02411717

Auro Pharma Inc.	Auro-Rufinamide	Banzel	RUFINAMIDE	200 mg	tablet	02545985
Auro Pharma Inc.	Auro-Rufinamide	banzel	RUFINAMIDE	400 mg	tablet	02545993
Jamp Pharma Corporation	Jamp Sumatriptan DF	Imitrex DF	SUMATRIPTAN SUCCINATE	25 mg	tablet	02545292
Jamp Pharma Corporation	Jamp Sumatriptan DF	Imitrex DF	SUMATRIPTAN SUCCINATE	50 mg	tablet	02545306
Jamp Pharma Corporation	Jamp Sumatriptan DF	Imitrex DF	SUMATRIPTAN SUCCINATE	100 mg	tablet	02545314
Nora Pharma	NRA-Olanzapine	Zyprexa	OLANZAPINE	20 mg	tablet	02545632